

# Certificate of Analysis



Level 2, 321 Kent Street, Sydney NSW 2000, Australia

Phone: +61 2 8228 2719  
Email: [info@geneabiomedx.com](mailto:info@geneabiomedx.com)  
Website: [geneabiomedx.com](http://geneabiomedx.com)

## Product Details

**Product description:** Cleavage Medium  
**Product code** CLM-20  
**Lot number:** J000007447  
**Expiry date:** 08 Jul. 2026

## Intended Use

Cleavage Medium is used to provide necessary nutrients for embryo development *in vitro*. The embryos can remain in this solution for up to 2 days prior to being transferred to the uterus or grown for up to another 3 days in Blastocyst Medium (BLM-20, BLM-50).

**USA only:** Gems Cleavage Medium is for *in vitro* culture of embryos following fertilisation to the 4-8 cell stage. This medium can be used for transfer of cleavage stage embryos into the uterus.

**Caution:** Federal law (USA) restricts this device to sale by or on the order of a physician or practitioner trained in its use.

## Product Analysis

Assay	Specification	Result
pH at 37 °C with 6% CO <sub>2</sub>	7.3 – 7.5	Pass
Osmolality	285 – 295 mOsm/kg	Pass
MEA	MEA (1-cell): ≥80% developed to blastocyst stage or beyond by 96 hours	Pass
Endotoxin	<0.40 EU/mL	Pass
Sterility	No Growth	Pass
HSA Analysis	3.75 – 6.25 mg/mL	Pass
Gentamicin	0.0075 – 0.0125 mg/mL	Pass

## Product passed and released by Quality

**Signature:**  Electronically signed by: Daire Dowling  
Reason: QA Approval  
Date: Aug 11, 2025 11:21:40 GMT+10

**Name:** Dáire Dowling  
**Job Title:** Quality Assurance Associate  
**Date:** 11 Aug. 2025








# Certificate of Analysis - J000007447

Final Audit Report

2025-08-11

Created:	2025-08-11 (Australian Eastern Standard Time)
By:	Daire Dowling (daire.dowling@geneabiomedx.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAX-twz1UfYJf8zpoywOE-vKBqYL9UMYAj

## "Certificate of Analysis - J000007447" History

-  Document created by Daire Dowling (daire.dowling@geneabiomedx.com)  
2025-08-11 - 11:20:11 AM GMT+10- IP address: 120.17.113.48
-  Document emailed to Daire Dowling (daire.dowling@geneabiomedx.com) for signature  
2025-08-11 - 11:20:31 AM GMT+10
-  Email viewed by Daire Dowling (daire.dowling@geneabiomedx.com)  
2025-08-11 - 11:20:37 AM GMT+10- IP address: 4.199.143.131
-  Daire Dowling (daire.dowling@geneabiomedx.com) authenticated with Adobe Acrobat Sign.  
Challenge: The user opened the agreement.  
2025-08-11 - 11:20:50 AM GMT+10
-  Daire Dowling (daire.dowling@geneabiomedx.com) authenticated with Adobe Acrobat Sign.  
Challenge: The user completed the signing ceremony.  
2025-08-11 - 11:21:39 AM GMT+10
-  Document e-signed by Daire Dowling (daire.dowling@geneabiomedx.com)  
Signing reason: QA Approval  
Signature Date: 2025-08-11 - 11:21:40 AM GMT+10 - Time Source: server- IP address: 120.17.113.48
-  Agreement completed.  
2025-08-11 - 11:21:40 AM GMT+10